American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SAN DIEGO, Dec. 18, 2017 -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI), effective prior to market open on Monday, December 18, 2017.
The Nasdaq Biotechnology Index (NBI) contains securities of Nasdaq-listed companies classified as either biotechnology or pharmaceutical, according to the Industry Classification Benchmark. Companies in the NBI must meet eligibility requirements, including minimum market capitalization and average daily trading volume, among other criteria. The NBI is re-ranked annually and forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares Nasdaq Biotechnology ETF. For more information about the NBI, visit https://indexes.nasdaqomx.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The company’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACTS
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
Kura Oncology, Inc.
(858) 500-8803
[email protected]
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
[email protected]
